专家简介:Melinda Telli, MD是NCCN乳腺癌指南专家组成员,来自美国斯坦福癌症研究所(SCI)。在2015年NCCN 年会上,Telli博士做主题报告:“三阴性乳腺癌治疗进展(Evolving Treatment Strategies?for Triple Negative Breast Cancer)”,并在报告结束后接受《肿瘤瞭望》采访。
Oncology Frontier:As a member of the NCCN guidelines panel, can you outline the recent changes that have occurred in the guidelines as they relate to triple-negative breast cancer?
《肿瘤瞭望》: NCCN乳腺癌指南在三阴性乳腺癌部分有无更新?
Dr Telli: There aren’t any major changes to the guidelines at this point in time related to triple-negative breast cancer, but I am hopeful that in the future, based on the results of this TNT trial in metastatic disease, that with longer follow-up and if the superior results in the BRCAmutation carrier population are maintained, then this will ultimately lead to a change in the guidelines with a preference for carboplatin in these advanced triple-negative breast cancer patients in the setting of a BRCAmutation. In the early stage setting with standard chemotherapy (anthracycline- and taxane-based), we need further studies to determine which patients should be standardly receiving platinum with newly diagnosed triple-negative breast cancer.
Telli博士:三阴性乳腺癌的最近没什么大的变化。在TNT试验以后随访中,若卡铂治疗BRCA突变转移性三阴乳腺癌的优良效果能继续保持,则有希望改变NCCN指南推荐。对于早期三阴性乳腺癌,还需要进一步研究以确定哪些初诊患者应接受标准铂类化疗。